Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Tumor lysis syndrome in multiple myeloma treated with bortezomib

    K. M. Dhanraj1★, Dubashi Biswajit1★ Corresponding author

    1. 1Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India Case Report.

    CORRESPONDENCE

    K. M. Dhanraj

    Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India Case Report.

    dhannu_doc@rediffmail.com

    Received: 17-02-2013; Revised: 10-09-2013; Accepted: 06-10-2013.

    Volume 5, Issue 2 · pp. 161–162 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.130091

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    A 65 year old male diagnosed as multiple myeloma was started on bortezomib developed tumor lysis syndrome. Bortezomib induced tumor lysis is rare and suitable precautions should be considered in these patients.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Dhanraj, K. M., & Biswajit, D. (2014). Tumor lysis syndrome in multiple myeloma treated with bortezomib. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 161–162. https://doi.org/10.4103/0976-500X.130091